BPC-157

No, and the distinction matters. These are compounded preparations made by licensed 503A pharmacies. The FDA does not verify the safety, effectiveness or quality of compounded medications — it regulates the pharmacies that make them, not the individual preparations. That is precisely why we publish what we do: because nobody else is verifying it for you, we release every batch against LC-MS/MS identity, HPLC potency to a 99.0% specification, LAL endotoxin, USP <71> sterility and USP <788> particulates, with mandatory sign-off. In July 2026 the FDA’s Pharmacy Compounding Advisory Committee voted to recommend several peptides — including BPC-157, TB-500, KPV and MOTS-c — for Category 1 compoundability. An advisory-committee recommendation is not an approval and not an endorsement of safety or efficacy. Epitalon and Semax were not part of that recommendation.

A 503A is a compounding pharmacy that prepares medications to order, for an individual patient, against a specific prescription. It is regulated under section 503A of the Federal Food, Drug, and Cosmetic Act and by state boards of pharmacy. It is not a manufacturer, and it does not make products for general sale.

Every lot is released against identity by LC-MS/MS, potency by HPLC against a 99.0% specification, endotoxin by LAL, sterility per USP <71>, and particulates per USP <788>. API is sourced only from Tier-1 U.S. and allied producers with an auditable certificate of analysis, chiral panel and residual-solvent data on every lot.

Yes. Every vial carries a lot number, and you can look that lot up on our verification page to see its release panel. That is the whole point of the company.

[TBD-LEGAL] The specific licensed entity, its state, and its permit number will be disclosed here before launch. We will not describe this in general terms when the specifics are what matter.